San Diego, California, November 24, 2025 — Capricor Therapeutics, Inc. announced new data at the AAEV 2025 meeting that demonstrated a scalable framework for loading therapeutic small interfering RNAs (siRNAs) and phosphorodiamidate morpholino oligomers (PMOs) into engineered exosomes, representing a potentially transformative step in exosome-based drug delivery technologies. The company’s news centres on its proprietary StealthX™ exosome platform, which was showcased in a poster presentation titled, “A Systematic Framework for the Scalable Loading of Therapeutic siRNA and PMO into Exosomes.” The data highlight both scale-up and scale-out electroporation strategies that maintain efficient loading of therapeutic cargo in significantly larger manufacturing volumes — a critical advancement for translating exosome therapeutics into the clinic and commercial realms. Capricor emphasises that establishing this reproducible and high-yield loading process is essential to advancing its pipeline of exosome-based therapeutics for rare diseases and broader applications.
Science Significance
Exosomes — naturally occurring extracellular vesicles secreted by cells — are increasingly recognised as promising delivery vehicles for a broad range of therapeutic modalities, including oligonucleotides, proteins, and small molecules. The science significance of Capricor’s announcement lies in addressing one of the major technical bottlenecks: scalable and reproducible loading of cargo into exosomes at clinically relevant volumes. The data show that engineered exosomes derived from 293F cell lines can be loaded with both siRNA and PMO using optimised electroporation conditions, and that these efficiencies hold when both scale-up (larger batch size) and scale-out (parallel production) strategies are applied. This breakthrough helps bridge the gap between promising preclinical results and manufacturing viability for exosome therapeutics — positioning the platform as a robust vehicle for next-generation oligonucleotide delivery across a broad spectrum of disease targets.
Regulatory Significance
From a regulatory perspective, demonstrating scalable manufacturing, reproducible loading processes, and consistent product quality are foundational for advancing therapeutic candidates through the regulatory pathway. The data support the notion that Capricor is aligning with Good Manufacturing Practice (GMP) frameworks for biologic/exosome production and addressing critical regulatory-manufacturing issues such as yield, batch consistency, potency, and traceability. These aspects strengthen the company’s readiness for IND-enabling studies and eventual clinical-trial filings. Regulators require robust processes for biologic or cell-derived therapies — including exosomes — and Capricor’s framework may help pave the way for industry standards in this emerging modality.
Business Significance
Advertisement
This development enhances Capricor’s business proposition by elevating its exosome platform from concept to commercially scalable technology. The ability to produce large-scale, loaded exosomes opens up opportunities for licensing partnerships, co-development deals, and pipeline expansion into oligonucleotide therapeutics, gene therapy adjuncts, vaccine platforms and more. By offering a validated manufacturing solution, Capricor strengthens its position in the competitive biotech ecosystem. Investors and strategic partners will view this milestone as evidence of differentiation and translational potential, supporting future commercial and corporate value creation.
Patients’ Significance
For patients, the implications are profound: the advancement of a scalable exosome-based delivery system has the potential to bring more targeted, less invasive, and more effective treatments to those with unmet needs. Whether in rare genetic diseases, cancer, neurological disorders or other therapeutic areas, exosome vehicles may enable precise delivery of oligonucleotides with better biodistribution, lower toxicity and improved efficacy. As Capricor moves toward clinical translation of its pipeline, the patient benefit lies in novel therapeutic options that could address previously untreatable conditions or improve on existing modalities with better safety and convenience.
Policy Significance
The announcement aligns with broader policy trends in regenerative medicine, advanced therapies, and biologics manufacturing innovation. Policymakers and regulatory agencies are increasingly focused on enabling platforms that support personalised medicine, biologic scalability, and next-gen delivery systems. Capricor’s achievement may influence public-policy discussion around manufacturing standards for exosome therapies, supply-chain resilience for advanced biologics, and regulatory frameworks for cell-derived therapeutic modalities. As governments aim to promote innovation while ensuring safety and scalability, developments such as this provide meaningful data to support evolving policy on advanced therapies.
Capricor Therapeutics’ presentation of a scalable framework for loading oligonucleotides into exosomes marks a significant step in the maturation of exosome-based therapeutic platforms. With innovative science, regulatory foresight, commercial potential and patient-centric promise, this milestone illustrates how the company is advancing toward introducing next-generation delivery systems. As the field of exosome therapeutics evolves, Capricor’s achievement stands as a timely example of how manufacturing scalability and translational readiness can be achieved in emerging modalities — offering hope for a wide array of future treatments.
Source: Capricor Therapeutics, Inc. press release
